Cara Therapeutics: Funding, Investors & Team (Oct 2026)
Cara Therapeutics is a company in the biopharmaceutical industry that is focused on improving the lives of patients who suffer from pruritus. They have developed an injection called KORSUVA® (difelikefalin) which is the only treatment approved by the FDA for moderate-to-severe pruritus in adults with chronic kidney disease who are undergoing hemodialysis. Additionally, the company is working on a version of difelikefalin that can be taken orally and is currently in Phase 3 trials for the treatment of pruritus in patients with advanced chronic kidney disease and atopic dermatitis. They have also started a Phase 2/3 program for an oral form of difelikefalin to treat moderate-to-severe pruritus in patients with notalgia paresthetica.
Cara Therapeutics has raised $40.0M across 1 funding round on record, the most recent an undisclosed round of $40.0M announced in Nov 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cara Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Cara Therapeutics Funding Rounds
Cara Therapeutics Founders and Leadership Team
Contact details for the Cara Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Cara Therapeutics Funding Compared to Other Biotechnology Startups
Cara Therapeutics' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cara Therapeutics in Biotechnology and Shelton
Companies Similar to Cara Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Cara Therapeutics Funding FAQs
What does Cara Therapeutics do?
Cara Therapeutics is a company in the biopharmaceutical industry that is focused on improving the lives of patients who suffer from pruritus. They have developed an injection called KORSUVA® (difelikefalin) which is the only treatment approved by the FDA for moderate-to-severe pruritus in adults with chronic kidney disease who are undergoing hemodialysis. Additionally, the company is working on a version of difelikefalin that can be taken orally and is currently in Phase 3 trials for the treatment of pruritus in patients with advanced chronic kidney disease and atopic dermatitis. They have also started a Phase 2/3 program for an oral form of difelikefalin to treat moderate-to-severe pruritus in patients with notalgia paresthetica.
How much funding has Cara Therapeutics raised?
Cara Therapeutics has raised $40.0M across 1 round on record. The most recent is an undisclosed round of $40.0M announced in Nov 2023.
When did Cara Therapeutics last raise funding?
Cara Therapeutics' most recent funding round on record is an undisclosed round of $40.0M, announced in Nov 2023.
Who founded Cara Therapeutics?
FundedIQ lists Michael E Lewis (Founder) at Cara Therapeutics.
Where is Cara Therapeutics headquartered?
Cara Therapeutics is based in Shelton, Connecticut, United States.
How many employees does Cara Therapeutics have?
Cara Therapeutics is in the 101-250 employee band.
How does Cara Therapeutics' funding compare to other Biotechnology startups?
Cara Therapeutics' latest round of $40.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Cara Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cara Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.